Markus Raderer

Research interests

Publications

• Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2020 · https://doi.org/10.1016/j.annonc.2019.10.010

• Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study

  The Lancet Oncology · 2018 · https://doi.org/10.1016/s1470-2045(18)30685-5

• A MALT lymphoma prognostic index

  Blood · 2017 · 10.1182/blood-2017-03-771915

• Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study

  Endocrine Related Cancer · 2016 · 10.1530/erc-15-0490

• Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality

  Heart · 2015 · 10.1136/heartjnl-2015-307848

• Clinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa‐associated lymphoid tissue (MALT lymphoma)

  CA A Cancer Journal for Clinicians · 2015 · 10.3322/caac.21330

• Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors

  New England Journal of Medicine · 2014 · https://doi.org/10.1056/nejmoa1316158

• Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2013 · 10.1093/annonc/mdt343

• ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)

  Annals of Oncology · 2012 · https://doi.org/10.1093/annonc/mds517

• EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT

  Gut · 2011 · https://doi.org/10.1136/gut.2010.224949

• Primary Follicular Lymphoma of the Duodenum Is a Distinct Mucosal/Submucosal Variant of Follicular Lymphoma: A Retrospective Study of 63 Cases

  Journal of Clinical Oncology · 2011 · 10.1200/jco.2010.32.9193

• Most patients with minimal histological residuals of gastric MALT lymphoma after successful eradication of Helicobacter pylori can be managed safely by a watch and wait strategy: experience from a large international series: Figure 1

  Gut · 2007 · 10.1136/gut.2006.096420

• Assessment of Disease Dissemination in Gastric Compared With Extragastric Mucosa-Associated Lymphoid Tissue Lymphoma Using Extensive Staging: A Single-Center Experience

  Journal of Clinical Oncology · 2006 · 10.1200/jco.2006.06.0723

• Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma

  Leukemia · 2005 · 10.1038/sj.leu.2404045

• T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma

  Leukemia · 2005 · https://doi.org/10.1038/sj.leu.2403644

• High Relapse Rate in Patients with MALT Lymphoma Warrants Lifelong Follow-up

  Clinical Cancer Research · 2005 · 10.1158/1078-0432.ccr-04-2282

• High Relapse Rate in Patients with MALT Lymphoma Warrants Lifelong Follow-up

  Clinical Cancer Research · 2005 · 10.1158/1078-0432.ccr-04-2282

• Palliative chemotherapy for advanced gastric cancer

  Annals of Oncology · 2004 · 10.1093/annonc/mdh422

• Variable frequencies of MALT lymphoma-associated genetic aberrations in MALT lymphomas of different sites

  Leukemia · 2004 · https://doi.org/10.1038/sj.leu.2403501

• Palliative chemotherapy for advanced gastric cancer

  Annals of Oncology · 2004 · 10.1093/annonc/mdh422

• Randomized Multicenter Phase II Trial of Two Different Schedules of Capecitabine Plus Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer

  Journal of Clinical Oncology · 2003 · 10.1200/jco.2003.09.016

• T(14;18)(q32;q21) involving IGH andMALT1 is a frequent chromosomal aberration in MALT lymphoma

  Blood · 2003 · https://doi.org/10.1182/blood-2002-09-2963

• Randomized Multicenter Phase II Trial of Two Different Schedules of Capecitabine Plus Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer

  Journal of Clinical Oncology · 2003 · 10.1200/jco.2003.09.016

• The impact of hemoglobin levels on fatigue and quality of life in cancer patients

  Annals of Oncology · 2002 · 10.1093/annonc/mdf122

• Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial

  Annals of Oncology · 2002 · 10.1093/annonc/mdg029

• The impact of hemoglobin levels on fatigue and quality of life in cancer patients

  Annals of Oncology · 2002 · 10.1093/annonc/mdf122

• Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer

  Annals of Oncology · 2001 · 10.1023/a:1008352123009

• Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer

  Annals of Oncology · 2001 · 10.1023/a:1008352123009

• Inhibition of Metastases by Anticoagulants

  JNCI Journal of the National Cancer Institute · 1999 · 10.1093/jnci/91.1.22

• Involvement of P-glycoprotein in the transmembrane transport of interleukin-2 (IL-2), IL-4, and interferon-gamma in normal human T lymphocytes

  Blood · 1996 · 10.1182/blood.v88.5.1747.1747

• Clinical trials of agents that reverse multidrug resistance. A literature review

  Cancer · 1993 · 10.1002/1097-0142(19931215)72:12<3553::aid-cncr2820721203>3.0.co;2-b

Current projects

No projects listed.